Aldehyde Dehydrogenases (ALDHs) belong to a family of enzymes that play a key role in the metabolism of endogenous and exogenous aldehydes. This group of intracellular enzymes plays a pivotal role in embryogenesis and cell differentiation as well as in cancer progression by mediating retinoic acid signalling. Their functional activity also extends to cellular redox homeostasis via detoxification of reactive aldehydes derived from lipid peroxidation and other metabolic processes thus, playing a major cytoprotective role in cells.


Read more



ABD-3001 is a suicidal inhibitor of ALDH1 and 3. It blocks the enzyme activity irreversibly causing rapid accumulation of reactive aldehydes in tumour cells, beyond critical threshold. The accumulated aldehydes, notably HNE and MDA form genotoxic adducts with protein and DNA affecting the oncogenic signalling pathways that participate in cell proliferation.


Read more

Our vision

Advanced Biodesign

Based on our expertise in cancer metabolism and know-how in specific cell death called “apoptosis”, we will develop a new way to treat cancer to overcome actual stratification of cancer to bring new hope for patient.  By focusing on rare or bad-prognostic cancer, Advanced BioDesign offer innovative therapy to target markets with high unmet medical needs in cancer.  


Advanced Biodesign announces the start of the First-In-Human Clinical Trial "ODYSSEY" targeting Acute Myeloid Leukaemia

After receiving an approval from the National Agency for Medicinal Safety and Health Products (ANSM), Advanced BioDesign announces today the enrolment of the first patient in its "ODYSSEY" (NCT05601726) First-In-Human clinical trial in acute myeloid leukemia (AML).

Read more
CRISPALDin Project

Advanced BioDesign and the Inserm TAGC laboratory will receive a total of €208,000 to support the development of their CRISPALDHin project over the next two years.CRISPALDHin project aims at developing adaptive and personalised treatments targeting multiple genomic alterations involving aldehyde dehydrogenases 1 (ALDH 1) which are at the root of cancer resistance. Lyon, 21st September 2022 – Advanced BioDesign, a French biotechnology company specialized in the development of a new therapy against cancers resisting standard treatments, and the TAGC (Theories and Approaches to Genomic Complexity) laboratory (U1090 University Aix-Marseille) will receive €208,000 in funding from the Relaunch France plan for their collaborative work on the CRISPALDHin project.

Read more